On October 30, 2026, the US Food and Drug Administration (FDA) expanded the indication of tildrakizumab-asmn (Ilumya) to include adults with active psoriatic arthritis (PsA). Already approved for moderate-to-severe plaque psoriasis, tildrakizumab selectively inhibits interleukin (IL)-23. Tildrakizumab was first FDA approved in March 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab also received FDA approval of supplemental biologics license applications in April 2024 and December 2025 to incorporate clinical trial data evaluating its efficacy and safety in scalp and nail psoriasis, respectively, into the prescribing information. These approvals did not establish separate indications; tildrakizumab’s approval for plaque psoriasis remains unchanged.
A New Option for Psoriatic Arthritis
Tildrakizumab’s approval offers another choice for patients with psoriatic disease, especially those struggling with joint symptoms. PsA is a chronic inflammatory condition affecting joints, entheses, and skin, with symptoms varying widely among patients. While existing treatments target TNF, IL-17, and IL-23, some patients still face inadequate responses or side effects.
Tildrakizumab, a humanized monoclonal antibody, binds to the p19 subunit of IL-23, disrupting its role in inflammation. This mechanism is similar to other IL-23 inhibitors like guselkumab, risankizumab, and mirikizumab. Its approval adds another option in this class, addressing the need for individualized therapy in PsA.
Read Also: Clinicians Seek Non-Federal Health Guidance Amid Trust Decline
Clinical Trials and Dosing
The FDA’s decision was based on two Phase 3 trials, INSPIRE-1 and INSPIRE-2, involving 806 adults with active PsA. Participants received either tildrakizumab 100 mg or a placebo every 12 weeks. At Week 24, tildrakizumab showed significantly better results than the placebo, with 38.8% of patients achieving at least a 20% improvement in symptoms (ACR20), compared to 24.4% on the placebo. Additionally, ACR50 and ACR70 response rates were 21.5% and 8.6%, respectively, versus 12.5% and 3.5% for placebo.
For patients with both PsA and plaque psoriasis, the dosing is 100 mg at weeks 0 and 4, followed by every 12 weeks. For PsA alone, the dose is 100 mg every 12 weeks. While the every-12-week schedule may reduce clinic visits, its impact on adherence or outcomes remains unclear.
Improvements in skin psoriasis were also observed. Among patients with at least 3% body surface area affected by psoriasis at baseline, Psoriasis Area and Severity Index (PASI) 75 response occurred in 41% receiving tildrakizumab vs 10.9% receiving placebo (P < .0001). The pooled difference in HAQ-Disability Index physical function score was –0.05 (P = 0.09), but it was not statistically significant.
Read Also: AI in healthcare risks widening disparities without stronger ethics
Common side effects included upper respiratory infections and COVID-19, occurring in at least 3% of patients, with no new safety concerns reported. Label warnings and precautions address hypersensitivity, increased risk of infections, pretreatment screening for tuberculosis, and avoiding the use of live vaccines.
Long-Term Efficacy and Safety Considerations
The INSPIRE trials demonstrated tildrakizumab’s effectiveness at 24 weeks, but its long-term efficacy and safety in PsA are still under scrutiny. The trials extended to 52 weeks, yet data beyond this period is limited. Sun Pharma reported no new safety signals in the Phase 3 program, consistent with its psoriasis profile. Longer-term and comparative safety evidence in PsA will remain relevant to treatment selection.
Clinical Positioning and Future Research
Tildrakizumab joins the IL-23 inhibitor class for PsA, alongside guselkumab, risankizumab, and mirikizumab. Its role in clinical practice will depend on emerging data and clinician experience. The every-12-week dosing may offer convenience, but its impact on adherence and patient preferences requires further study.
